Home/ Stocks/ ATOS

Atossa Therapeutics, Inc. Common Stock

ATOS XNAS

$2.36 -0.15 (-6.32%) ▼ 15-min delayed

Open

$2.37

High

$2.45

Low

$2.24

Volume

78.0K

Market Cap

$24.14M

About Atossa Therapeutics, Inc. Common Stock

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 14 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-9,589,000	$-1.11
FY 2025	$0	$-34,770,000	$-4.04
Q3 2025	$0	$-8,692,000	$-0.07
Q2 2025	$0	$-8,423,000	$-0.07

Related Market News

No specific coverage for ATOS yet. Check out our latest market news or earnings calendar.

Get ATOS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Atossa Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.